Drug Trial Radar · NCT00067561
Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
Last checked: Nov 19, 2026Latest source record: Apr 16, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
702
Actual
Start
Jun 2003
Primary completion
Jan 2005
Study completion Jan 2005
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 25, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the safety and effectiveness of different doses of an investigational medication in women with severe diarrhea-predominant Irritable Bowel Syndrome (IBS) who have failed conventional therapy.
Conditions
- Irritable Colon
- Irritable Bowel Syndrome (IBS)
Interventions
AlosetronDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subject self assessment of improvement between treatment groups using the IBS Global Improvement Scale; comparison of safety and tolerability between treatment groups with respect to adverse events & laboratory abnormalities.
Locations
178 sites in 2 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Calera, Alabama
GSK Investigational Site
Tuscaloosa, Alabama
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Fayetteville, Arkansas
GSK Investigational Site
Chula Vista, California
GSK Investigational Site
Fountain Valley, California
GSK Investigational Site
Garden Grove, California
GSK Investigational Site
Lancaster, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Newport Beach, California
GSK Investigational Site
Rancho Cucamonga, California
GSK Investigational Site
Redlands, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Rafael, California
GSK Investigational Site
Santa Ana, California
GSK Investigational Site
Santa Ana, California
GSK Investigational Site
Upland, California
GSK Investigational Site
Vista, California
GSK Investigational Site
Yuba City, California
GSK Investigational Site
Boulder, Colorado
GSK Investigational Site
Colorado Springs, Colorado
GSK Investigational Site
Colorado Springs, Colorado
GSK Investigational Site
Englewood, Colorado
GSK Investigational Site
Wheat Ridge, Colorado
GSK Investigational Site
Manchester, Connecticut
GSK Investigational Site
Boca Raton, Florida
GSK Investigational Site
Boynton Beach, Florida
GSK Investigational Site
Boynton Beach, Florida
GSK Investigational Site
Coral Gables, Florida
GSK Investigational Site
Fort Myers, Florida
GSK Investigational Site
Fort Myers, Florida
GSK Investigational Site
Hialeah, Florida
GSK Investigational Site
Hollywood, Florida
GSK Investigational Site
Lake Worth, Florida
GSK Investigational Site
Longwood, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
Showing 40 of 178 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.